MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
STERIS plc Operating Income 2011-2025 | STE
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income STERIS plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 867 M | 836 M | 791 M | 478 M | 548 M | 537 M | 411 M | 400 M | 226 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 867 M | 226 M | 566 M |
Quarterly Operating Income STERIS plc
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 266 M | 246 M | - | 245 M | 220 M | 186 M | - | 226 M | 192 M | 198 M | - | 191 M | -306 M | 158 M | - | 203 M | 334 M | 131 M | - | 147 M | 147 M | 141 M | 114 M | 142 M | 142 M | 127 M | 110 M | 69.6 M | 107 M | 94.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 334 M | -306 M | 153 M |
Operating Income of other stocks in the Medical instruments industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Baxter International
BAX
|
14 M | $ 19.29 | -0.46 % | $ 9.84 B |  USA |
 |
Becton, Dickinson and Company
BDX
|
2.58 B | $ 195.87 | -0.23 % | $ 56.3 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
-10.5 M | $ 5.47 | -1.59 % | $ 110 M | USA |
 |
Harvard Bioscience
HBIO
|
1.89 M | $ 0.68 | -2.76 % | $ 28.8 M | USA |
 |
Repro Med Systems
KRMD
|
-10.3 M | $ 6.08 | -2.45 % | $ 277 M | USA |
 |
LeMaitre Vascular
LMAT
|
52.3 M | $ 83.83 | 0.06 % | $ 1.88 B | USA |
 |
Masimo Corporation
MASI
|
-267 M | $ 132.25 | -0.38 % | $ 7.05 B | USA |
 |
Alcon
ALC
|
580 M | $ 80.62 | 0.3 % | $ 40.4 B |  Schweiz |
 |
iRhythm Technologies
IRTC
|
-116 M | $ 178.51 | 1.08 % | $ 5.57 B | USA |
 |
Merit Medical Systems
MMSI
|
156 M | $ 88.07 | 0.78 % | $ 5.13 B | USA |
 |
ICU Medical
ICUI
|
43 M | $ 147.97 | 0.06 % | $ 3.61 B | USA |
 |
AtriCure
ATRC
|
-40 M | $ 41.15 | 2.03 % | $ 1.93 B | USA |
 |
Atrion Corporation
ATRI
|
22.6 K | - | - | $ 810 M | USA |
 |
electroCore
ECOR
|
-19.3 M | $ 4.86 | -1.82 % | $ 26.8 K | USA |
 |
Isoray
ISR
|
-90.9 M | - | 0.03 % | $ 108 M | USA |
 |
AngioDynamics
ANGO
|
-40 M | $ 12.97 | -0.99 % | $ 530 M | USA |
 |
OraSure Technologies
OSUR
|
-28.2 M | $ 2.42 | - | $ 180 M | USA |
 |
The Cooper Companies
COO
|
683 M | $ 82.06 | -0.68 % | $ 16.3 B | USA |
 |
Glaukos Corporation
GKOS
|
-129 M | $ 116.61 | 0.34 % | $ 5.65 B | USA |
 |
Haemonetics Corporation
HAE
|
222 M | $ 79.78 | -0.62 % | $ 4.02 B | USA |
 |
InfuSystem Holdings
INFU
|
1.65 M | $ 8.82 | -1.56 % | $ 182 M | USA |
 |
ResMed
RMD
|
1 B | $ 245.01 | 0.1 % | $ 35.8 B | USA |
 |
Intuitive Surgical
ISRG
|
2.35 B | $ 577.91 | 0.02 % | $ 205 B | USA |
 |
Microbot Medical
MBOT
|
-9.86 M | $ 2.09 | -2.84 % | $ 21.3 M |  Israel |
 |
Utah Medical Products
UTMD
|
16.8 M | $ 56.54 | -0.37 % | $ 205 M | USA |
 |
Milestone Scientific
MLSS
|
-6.76 M | $ 0.29 | -1.35 % | $ 23.1 M | USA |
 |
Nephros
NEPH
|
-1.59 M | $ 5.0 | 1.42 % | $ 51.9 M | USA |
 |
NeuroMetrix
NURO
|
-8.78 M | - | 5.05 % | $ 9.02 M | USA |
 |
Envista Holdings Corporation
NVST
|
-1.04 B | $ 21.94 | -0.23 % | $ 3.78 B | USA |
 |
Predictive Oncology
POAI
|
-10.9 M | - | - | $ 32.4 M | USA |
 |
Stereotaxis
STXS
|
-21.8 M | $ 2.41 | -2.03 % | $ 194 M | USA |
 |
Pro-Dex
PDEX
|
10.7 M | $ 39.3 | -0.38 % | $ 129 M | USA |
 |
Pulse Biosciences
PLSE
|
-43.6 M | $ 14.59 | 1.32 % | $ 701 M | USA |
 |
Repligen Corporation
RGEN
|
47.7 M | $ 165.84 | -0.22 % | $ 9.24 M | USA |
 |
BioLife Solutions
BLFS
|
-7.13 M | $ 25.04 | 0.56 % | $ 1.15 B | USA |
 |
Retractable Technologies
RVP
|
-21.1 M | $ 0.82 | -2.16 % | $ 24.5 M | USA |
 |
STAAR Surgical Company
STAA
|
-12.6 M | $ 23.55 | 0.86 % | $ 1.16 B | USA |
 |
Teleflex Incorporated
TFX
|
151 M | $ 123.02 | 0.21 % | $ 5.76 B | USA |
 |
West Pharmaceutical Services
WST
|
570 M | $ 274.89 | 0.22 % | $ 20.1 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
-879 M | $ 11.44 | -0.74 % | $ 2.32 B | USA |